| Autor: |
Lefebvre AL; Clinical Pharmacist Specialist, Ambulatory Care, Department of Pharmacy, Rhode Island Hospital, Providence, RI., McAuliffe L; Ambulatory Care Pharmacy Resident, Department of Pharmacy, Rhode Island Hospital, Providence, RI. |
| Jazyk: |
angličtina |
| Zdroj: |
Rhode Island medical journal (2013) [R I Med J (2013)] 2016 Dec 01; Vol. 99 (12), pp. 19-22. Date of Electronic Publication: 2016 Dec 01. |
| Abstrakt: |
Monoclonal antibodies and other biologic response modifiers have allowed for targeted drug therapy in managing various autoimmune diseases. A number of immune pathways have been exploited in the development of targeted immunomodulatory therapies, including cytokine-directed therapies such as tumor necrosis factor-alpha and interleukins, integrins, B-cells, and co-stimulation modulators. With new targeted therapies in the pipeline, more options are becoming available for treatment of autoimmune diseases. [Full article available at http://rimed.org/rimedicaljournal-2016-12.asp]. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
